Information Provided By:
Fly News Breaks for April 15, 2018
ALNY
Apr 15, 2018 | 19:19 EDT
Piper Jaffray analyst Edward Tenthoff notes that Alnylam presented updated Phase I and preliminary OLE data on givosiran in acute hepatic porphyria. The analyst believes the results have strong read-through to the ongoing Phase III ENVISION trial, which is on-track to report interim data in mid'18 that could support an NDA filing by YE18 and accelerated approval in 2019. Tenthoff remains confident in broad patisiran approval in ATTR amyloidosis by the August 11 PDUFA. He reiterates an Overweight rating and $182 price target on the shares.
News For ALNY From the Last 2 Days
There are no results for your query ALNY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.